Article Details

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman ...

Retrieved on: 2024-09-25 22:18:13

Tags for this article:

Click the tags to see associated articles and topics

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman .... View article details on hiswai:

Excerpt

Last week, Ascendis Pharma A/S (NASDAQ:ASND) released topline data on Monday from a trial that included 84 children with achondroplasia, ...

Article found on: www.aol.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up